Valproate
Unchecked
Valproate (valproic acid, divalproex sodium, sodium valproate)
Depakote, Depakote ER, Depakene, Depacon (IV)
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Generalized epilepsy (absence, tonic-clonic, myoclonic)0, Focal epilepsy0, Bipolar disorder (acute mania, maintenance)0, Migraine prophylaxis0, Status epilepticus (IV)0
Pharmacy
Starting dose
Seizures: 10-15 mg/kg/d divided BID-TID, titrate to therapeutic level (50-100 mcg/mL); bipolar mania: 750 mg/d divided, titrate
Preparations
125, 250, 500 mg delayed-release tablets (Depakote); 250, 500 mg ER tablets (Depakote ER); 125, 250 mg sprinkle capsules; 250 mg/5 mL syrup; 500 mg IV (Depacon)
US FDA Max
60 mg/kg/d (typically up to 3000 mg/d)
Pharmacology
Routes
Oral, IV, rectal (off-label use of injection)
Onset
Anticonvulsant effect within days; mood-stabilizing effect 1-3 weeks
Duration
12 hours (IR); 24 hours (ER)
Half-life
9-16 hours[1]
Bioavailability
~100% (oral); highly (~90%) protein-bound, with non-linear binding above therapeutic levels (free fraction matters clinically in hypoalbuminemia)[1]
Pregnancy
Contraindicated for migraine prophylaxis in pregnancy; high teratogenic risk (neural tube defects, craniofacial anomalies, cardiac defects, cognitive/IQ impairment); avoid in women of childbearing potential without reliable contraception when alternatives exist[1]
Legal status
Purported mechanism
Valproate broadens GABAergic inhibition (raises GABA synthesis, inhibits degradation), blocks voltage-gated sodium channels (slow-inactivated state preference), blocks T-type calcium channels (relevant to absence seizures), and inhibits histone deacetylases (postulated mood-stabilizer mechanism); the multi-mechanism profile underlies the broad-spectrum anticonvulsant activity.0 Hyperammonemic encephalopathy (consider in any unexplained CNS depression), thrombocytopenia, and polycystic ovary syndrome are characteristic chronic-use adverse effects beyond hepatic and pancreatic risks[1].